Arama Sonuçları - Emily Robitschek

  • Gösterilen 1 - 4 sonuçlar arası kayıtlar. 4
Sonuçları Daraltın
  1. 1
    Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade

    Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade Yazar: Jeffrey J. Ishizuka, Robert T. Manguso, Collins Cheruiyot, Kevin Bi, Arpit Panda, Arvin Iracheta‐Vellve, Brian C. Miller, Peter P. Du, Kathleen B. Yates, Juan Dubrot, Ilana Buchumenski, Dawn E. Comstock, Flavian D. Brown, Austin Ayer, Ian C. Kohnle, Hans W. Pope, Margaret D. Zimmer, Debattama R. Sen, Sarah Kate Lane-Reticker, Emily Robitschek, Gabriel K. Griffin, Natalie B. Collins, Adrienne H. Long, John G. Doench, David Kozono, Erez Y. Levanon, W. Nicholas Haining

    Baskı/Yayın Bilgisi 2018
    Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  2. 2
    Epigenetic silencing by SETDB1 suppresses tumour intrinsic immunogenicity

    Epigenetic silencing by SETDB1 suppresses tumour intrinsic immunogenicity Yazar: Gabriel K. Griffin, Jingyi Wu, Arvin Iracheta‐Vellve, James C. Patti, Jeffrey Hsu, Thomas Davis, Deborah Dele‐Oni, Peter P. Du, Aya Halawi, Jeffrey J. Ishizuka, Sarah Kim, Susan Klaeger, Nelson H. Knudsen, Brian C. Miller, Tung H. Nguyen, Kira E. Olander, Malvina Papanastasiou, Suzanna Rachimi, Emily Robitschek, Emily M. Schneider, Mitchell D. Yeary, Margaret D. Zimmer, Jacob D. Jaffe, Steven A. Carr, John G. Doench, W. Nicholas Haining, Kathleen B. Yates, Robert T. Manguso, B Bernstein

    Baskı/Yayın Bilgisi 2021
    Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  3. 3
    Evolution of delayed resistance to immunotherapy in a melanoma responder

    Evolution of delayed resistance to immunotherapy in a melanoma responder Yazar: David Liu, Jia‐Ren Lin, Emily Robitschek, Gyulnara G. Kasumova, Alex Heyde, Alvin Shi, Adam Kraya, Gao Zhang, Tabea Moll, Dennie T. Frederick, Yu‐An Chen, Shu Wang, Denis Schapiro, Li-Lun Ho, Kevin Bi, Avinash Sahu, Shaolin Mei, Benchun Miao, Tatyana Sharova, Christopher Alvarez‐Breckenridge, Jackson H. Stocking, Tommy Kim, Riley Fadden, Donald P. Lawrence, Mai P. Hoang, Daniel P. Cahill, Mohsen Malehmir, Martin A. Nowak, Priscilla K. Brastianos, Christine G. Lian, Eytan Ruppin, Benjamin Izar, Meenhard Herlyn, Eliezer M. Van Allen, Katherine L. Nathanson, Keith T. Flaherty, Ryan J. Sullivan, Manolis Kellis, Peter K. Sorger, Genevieve M. Boland

    Baskı/Yayın Bilgisi 2021
    Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  4. 4
    Targeting TBK1 to overcome resistance to cancer immunotherapy

    Targeting TBK1 to overcome resistance to cancer immunotherapy Yazar: Yi Sun, Or‐Yam Revach, Seth Anderson, Emily Kessler, Clara Wolfe, Anne Jenney, Caitlin E. Mills, Emily Robitschek, Thomas Davis, Sarah Kim, Amina Fu, Xiang Ma, Jia Gwee, Payal Tiwari, Peter P. Du, Princy Sindurakar, Jun Tian, Arnav Mehta, Alexis M. Schneider, Keren Yizhak, Moshe Sade-Feldman, Thomas J. LaSalle, Tatyana Sharova, Hongyan Xie, Shuming Liu, William A. Michaud, Rodrigo Saad-Beretta, Kathleen B. Yates, Arvin Iracheta‐Vellve, Johan Spetz, Xingping Qin, Kristopher A. Sarosiek, Gao Zhang, Jong Wook Kim, Mack Y. Su, Angelina M. Cicerchia, Martin Q. Rasmussen, Samuel J. Klempner, Dejan Juric, Sara I. Pai, David M. Miller, Anita Giobbie‐Hurder, Jonathan H. Chen, Karin Pelka, Dennie T. Frederick, Susanna Stinson, Elena Ivanova, Amir Reza Aref, Cloud P. Paweletz, David A. Barbie, Debattama R. Sen, David E. Fisher, Ryan B. Corcoran, Nir Hacohen, Peter K. Sorger, Keith T. Flaherty, Genevieve M. Boland, Robert T. Manguso, Russell W. Jenkins

    Baskı/Yayın Bilgisi 2023
    Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:

Arama Araçları: